drugset / Trial / NCT01510769

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

NCT01510769

Phase 3 Completed 330 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.

Timeline

Start
2012-01
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 200 mg
Subject Lesinurad Small molecule 400 mg
Background Febuxostat Small molecule 80 mg

Indications